Saltar al contenido
PivotalWire
Domingo 22 nov 2026SEC · NASDAQ biomédico

Calendario›BNTX›BNT162b5 Bivalent

BNT162b5 Bivalent

Ensayo de BioNTech SE en Infección por SARS-CoV-2 · COVID-19.

Más ensayos de: COVID-19.

Fase
Fase 2/3
Estado
Completado
Participantes
1.453
previstos
Centros
31
Fin del objetivo primario
mar 2024
fecha real

Título oficial en el registro (en inglés): A Study to Learn About New COVID-19 RNA Vaccine Candidates in COVID-19 Vaccine-Experienced Healthy Individuals

Qué significa cada fase y cada estado.

Estudio de intervención, aleatorizado, cuádruple ciego. Comenzó en jul 2022.

De principio a fin

  1. Empieza el ensayo (jul 2022)
  2. Lectura de resultados mar 2024 (real)
  3. Hoy

Los cambios los anota PivotalWire desde agosto de 2026; lo anterior no lo tenemos. El historial completo, versión a versión, está en ClinicalTrials.gov.

Qué mide

Cohorte 1: Porcentaje de participantes que reportaron reacciones locales dentro de los 7 dias posteriores a la vacunacion del estudio (From Day 1 to Day 7 after study vaccination) (del registro, en inglés)

Qué se prueba

Este estudio busca conocer la seguridad, la tolerancia y la inmunogenicidad de unos candidatos a vacuna de ARN contra la COVID-19 en adultos.

Lo que dice el documentoto learn about the safety, tolerability and immunogenicity of BNT162b RNA-based SARS-CoV-2 vaccine candidates in adults to prevent COVID-19.

Traducción automática (claude-haiku-5-5). Lo comprobado es la cita: está literal en el documento y sus cifras cuadran con las de la frase. Todavía no la ha leído una persona.

Cómo lo describe el promotor

En el documentoEn inglés, del registroThe purpose of this clinical trial is to learn about the safety, tolerability and immunogenicity of BNT162b RNA-based SARS-CoV-2 vaccine candidates in adults to prevent COVID-19. For all cohorts (groups of participants), this study is seeking participants who are healthy (who may have preexisting disease if it is stable); All participants will receive a single dose of the study vaccine at the first study clinic and will return to the study clinic at least 4 more times. At each clinic visit, a blood sample will be taken. The study is about 6 months long for each participant. The vaccine candidates in this study are investigational but are very similar to BNT162b2 (Comirnaty), a COVID-19 RNA vaccine approved for use in the US and in many countries. For Cohort 1, this study included participants who were: * 18 through 55 years of age * have received 1 booster dose of a US-authorized COVID-19 vaccine, with the last dose being 90 or more days before Visit 1 of this study. All participants in Cohort 1 will receive 1 of the 2 study vaccines at a 30 microgram dose: BNT162b5 Bivalent (WT/OMI BA.2) or BNT162b2 Bivalent (WT/OMI BA.1). For Cohort 2, this study included participants who were: * 12 years of age and older * have received 3 prior doses of 30 micrograms BNT162b2, with the last dose being 150 to 365 days before Visit 1 of this study. Participants 12 through 17 years of age will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 micrograms. Participants 18 years and older will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) at either a 30 microgram or a 60 microgram dose. For Cohort 3, this study included participants who were: * 18 years of age and older * have received 3 prior doses of 30 micrograms BNT162b2, with the last dose being 150 to 365 days before Visit 1 of this study. * Participants will receive BNT162b2 Bivalent (WT/OMI BA.4/BA.5) 30 micrograms. For Cohort 4, this study is seeking participants who are: * 18 through 55 years of age * have received 3 or 4 prior doses of a US-authorized mRNA COVID-19 vaccine (and dose level), with the last dose being a US-authorized BA.4/BA.5-adapted bivalent vaccine and dose level at least 150 days before Visit 1 of this study. All participants in Cohort 4 will receive 1 of the 5 study vaccines at a 30 microgram dose: BNT162b2 Bivalent (Original/ OMI BA.4/BA.5), BNT162b5 Bivalent (Original/OMI BA.4/BA.5), BNT162b6 Bivalent (Original/OMI BA.4/BA.5), BNT162b7 Bivalent (Original/OMI BA.4/BA.5) or BNT162b7 Monovalent (OMI BA.4/BA.5).

Sigue a BNTX y recibe cada mañana en tu correo lo que haya presentado ante la SEC, en castellano. Crear una cuenta. ¿Ya tienes cuenta? Entrar.

Más ensayos de BNTX

EnsayoFaseEstadoLectura de resultados
BNT164a1Fase 1/2En marcha, sin reclutarmar 2026 (real)
BNT314Fase 1En marcha, sin reclutarago 2026 (real)
BNT163Fase 1En marcha, sin reclutaroct 2026 (prevista, ya pasada: sin actualizar en el registro)
RO7198457 intravenousFase 2En marcha, sin reclutarnov 2026 (prevista)
BNT351Fase 1Reclutando pacientesnov 2026 (prevista)
BNT162b2Fase 3En marcha, sin reclutarabr 2027 (prevista)

Todos los de BNTX, en su ficha.

Ficha completa en ClinicalTrials.gov (NCT05472038), actualizada en sep 2025.